Drug Topics e-News:
Having trouble viewing this email? View in a browser.
|
You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.
|
to Drug Topics e-News
|
|
|
|
 |
 |
| Newest: Diabetic peripheral neuropathy |
| For pharmacists, from Drug Topics: Continuing education for pharmacists and pharmacy technicians. Go to CE site here |
|
|
|
Survey
This month we would like to know...
The American College of Chest Physicians recommends immediate use of anticoagulants after major orthopedic replacement surgery and extended use post-discharge (at least 10 days for knee replacement and up to 35 days for hip replacement) to help reduce such risks as DVT and pulmonary embolism. Does your health system follow these guidelines?
|
|
|
FDA has received reports of serious central nervous system reactions when methylene blue is given to patients taking serotonergic psychiatric medications. Read full article. |
 |
|
|
To confirm your e-newsletter subscription, click here.
To ensure future delivery of email newsletters from
Drug Topics, please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff
|
 |
A monthly review of the
peer-reviewed literature by
Drug Topics' Editorial Advisor
Anna D. Garrett, PharmD, BCPS. Anna Garrett is manager, Outpatient Clinical Pharmacy Programs, Mission Hospital, Asheville, N.C.
|
Small study shows benefit of warfarin for cluster headaches.
Read full article.
|
FDA has approved ticagrelor (Brilinta, AstraZeneca) tablets to reduce the rate of heart attack and cardiovascular death in adult patients with acute coronary syndrome. Read full article. |
|
Improved glycemic control may help prevent heart failure, according to a recent study published in The Lancet. Read full article. |
|
Bristol-Myers Squibb has informed healthcare professionals about the Risk Evaluation and Mitigation Strategy (REMS) for belatacept (Nulojix) required by FDA to ensure that the benefits outweigh the risks for transplant patients who receive the drug. Read full article. |
|
On June 15, FDA published an online safety communication informing prescribers and patients that use of pioglitazone (Actos, Takeda Pharmaceuticals America Inc.) may be associated with a 20% to 40% increased hazard of new bladder cancer. Read full article. |
 |
Meetings and Events
August 3-6, 2011 AADE Annual meeting and exhibition
Las Vegas
Contact:
800-338-3633 ext. 4878.
[email protected]
August 27-30, 2011 NACDS Pharmacy & Technology Conference
Boston
Contact:
P.O. Box 34814
Alexandria, VA 22334-0814
703-683-5678
October 6-7, 2011 NCPA Diabetes Accreditation
Standards-Practical Applications (DASPA)
Nashville, TN
Contact:
100 Daingerfield Road
Alexandria, VA 22314
800-544-7447
October 8-12 2011 NCPA Annual Convention
Nashville, TN
Contact:
100 Daingerfield Road
Alexandria, VA 22314
800-544-7447
November 29, 2011 NACDS Foundation 13th Annual Dinner
New York, NY
Contact:
Jennifer Sargeant, Manager, Foundation Programs and Education, NACDS
703-837-4224
|
|
|
|
| Contact Us |
Contact a Drug Topics editor Click Here
Contact a Drug Topics sales representative Click Here
Learn about direct mail, reprints and classifieds in Drug Topics Click Here |
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
